Hannah Smith
Dr Elaine Willmore
Dr Lisa Prendergast
Professor Nicola Curtin
| ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors | 2024 |
|
Dr Nicola Johnson
Dr Johanne Bentley
Lan Wang
Professor Craig Robson
Professor Nicola Curtin
| Editorial Expression of Concern: Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells (British Journal of Cancer, (2010), 102, 2, (342-350), 10.1038/sj.bjc.6605479) | 2024 |
|
Maryam Zanjirband Zanjirband
Professor Nicola Curtin
Professor John Lunec
| Erratum: Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer (Oncotarget (2017) 8 41 (69779-69796)) | 2024 |
|
Professor Nicola Curtin
| The PARP inhibitor rucaparib blocks SARS-CoV-2 virus binding to cells and the immune reaction in models of COVID-19 | 2024 |
|
Dr Santu Saha
Dr Stuart Rundle
Dr Ioannis Kotsopoulos
Dr Jake Begbie
Rachel Howarth
et al. | Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy | 2022 |
|
Hannah Smith
Dr Elaine Willmore
Dr Asima Mukhopadhyay
Dr Yvette Drew
Professor Nicola Curtin
| Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling | 2022 |
|
Dr Christopher Morris
Professor Nicola Curtin
| Radiotherapy biobanking: current landscape, opportunities, challenges, and future aspirations | 2022 |
|
Alice Bradbury
Professor Nicola Curtin
Dr Yvette Drew
| The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response | 2022 |
|
Dr Sweta Sharma Saha
Lucy Gentles
Dominik Brecht
Dr Rachel O'Donnell
Professor Nicola Curtin
et al. | Genomic, transcriptomic, and functional alterations in DNA damage response pathways as putative biomarkers of chemotherapy response in ovarian cancer | 2021 |
|
Harriet Southgate
Dr Lindi Chen
Professor Nicola Curtin
Professor Deborah Tweddle
| Increased replication stress determines ATR inhibitor sensitivity in neuroblastoma cells | 2021 |
|
Lucy Gentles
Professor Nicola Curtin
Dr Yvette Drew
Dr Rachel O'Donnell
| Integration of computer-aided automated analysis algorithms in the development and validation of immunohistochemistry biomarkers in ovarian cancer | 2021 |
|
Harriet Southgate
Dr Lindi Chen
Professor Deborah Tweddle
Professor Nicola Curtin
| ATR inhibition potentiates parp inhibitor cytotoxicity in high risk neuroblastoma cell lines by multiple mechanisms | 2020 |
|
Alice Bradbury
Dr Rachel O'Donnell
Dr Yvette Drew
Professor Nicola Curtin
Dr Sweta Sharma Saha
| Characterisation of ovarian cancer cell line NIH-OVCAR3 and implications of genomic, transcriptomic, proteomic and functional DNA damage response biomarkers for therapeutic targeting | 2020 |
|
Hannah Smith
Harriet Southgate
Professor Deborah Tweddle
Professor Nicola Curtin
| DNA damage checkpoint kinases in cancer | 2020 |
|
Dr Santu Saha
Rachel Howarth
Dr Isabel Pappworth
Lucy Gentles
Professor Kevin Marchbank
et al. | Exploring rucaparib as chemo-radiosensitiser to increase therapeutic ratio in cervical cancer. | 2020 |
|
